Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

15 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Insight into the mechanism of CD34+ cell mobilisation impairment in multiple myeloma patients treated with anti-CD38 therapy.
Venglar O, Kapustova V, Anilkumar Sithara A, Zihala D, Muronova L, Sevcikova T, Vrana J, Vdovin A, Radocha J, Krhovska P, Hrdinka M, Turjap M, Popkova T, Chyra Z, Broskevicova L, Simicek M, Koristek Z, Hajek R, Jelinek T. Venglar O, et al. Among authors: krhovska p. Br J Haematol. 2024 Apr;204(4):1439-1449. doi: 10.1111/bjh.19141. Epub 2023 Oct 9. Br J Haematol. 2024. PMID: 37807708
Identification of patients at high risk of secondary extramedullary multiple myeloma development.
Stork M, Sevcikova S, Minarik J, Krhovska P, Radocha J, Pospisilova L, Brozova L, Jarkovsky J, Spicka I, Straub J, Pavlicek P, Jungova A, Jelinek T, Sandecka V, Maisnar V, Hajek R, Pour L. Stork M, et al. Among authors: krhovska p. Br J Haematol. 2022 Feb;196(4):954-962. doi: 10.1111/bjh.17925. Epub 2021 Nov 2. Br J Haematol. 2022. PMID: 34726261 Free PMC article.
Ixazomib, Lenalidomide and Dexamethasone in Relapsed and Refractory Multiple Myeloma in Routine Clinical Practice: Extended Follow-Up Analysis and the Results of Subsequent Therapy.
Minarik J, Radocha J, Jungova A, Straub J, Jelinek T, Pika T, Pour L, Pavlicek P, Harvanova L, Pospisilova L, Krhovska P, Novakova D, Jindra P, Spicka I, Plonkova H, Stork M, Bacovsky J, Maisnar V, Hajek R. Minarik J, et al. Among authors: krhovska p. Cancers (Basel). 2022 Oct 21;14(20):5165. doi: 10.3390/cancers14205165. Cancers (Basel). 2022. PMID: 36291949 Free PMC article.
Single agent daratumumab in advanced multiple myeloma possesses significant efficacy even in an unselected "real-world" population.
Minarik J, Pour L, Maisnar V, Spicka I, Jungova A, Jelinek T, Brozova L, Krhovska P, Scudla V, Hajek R. Minarik J, et al. Among authors: krhovska p. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2019 Sep;163(3):279-283. doi: 10.5507/bp.2018.064. Epub 2018 Nov 6. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2019. PMID: 30397362 Free article.
Survival benefit of ixazomib, lenalidomide and dexamethasone (IRD) over lenalidomide and dexamethasone (Rd) in relapsed and refractory multiple myeloma patients in routine clinical practice.
Minarik J, Pika T, Radocha J, Jungova A, Straub J, Jelinek T, Pour L, Pavlicek P, Mistrik M, Brozova L, Krhovska P, Machalkova K, Jindra P, Spicka I, Plonkova H, Stork M, Bacovsky J, Capkova L, Sykora M, Kessler P, Stejskal L, Heindorfer A, Ullrychova J, Skacel T, Maisnar V, Hajek R. Minarik J, et al. Among authors: krhovska p. BMC Cancer. 2021 Jan 15;21(1):73. doi: 10.1186/s12885-020-07732-1. BMC Cancer. 2021. PMID: 33451293 Free PMC article.
Urine immunofixation negativity is not necessary for complete response in intact immunoglobulin multiple myeloma: Retrospective real-world confirmation.
Radocha J, Jelinek T, Pour L, Spicka I, Minarik J, Popkova T, Jungova A, Pavlicek P, Brozova L, Stork M, Sedlak F, Krhovska P, Maisnar V, Heindorfer A, Sykora M, Wrobel M, Mikula P, Kessler P, Ullrychova J, Hajek R. Radocha J, et al. Among authors: krhovska p. Int J Lab Hematol. 2021 Oct;43(5):e244-e247. doi: 10.1111/ijlh.13460. Epub 2021 Jan 16. Int J Lab Hematol. 2021. PMID: 33452712 No abstract available.
Diagnostic deep-targeted next-generation sequencing assessment of TP53 gene mutations in multiple myeloma from the whole bone marrow.
Petrackova A, Minarik J, Sedlarikova L, Libigerova T, Hamplova A, Krhovska P, Balcarkova J, Pika T, Papajik T, Kriegova E. Petrackova A, et al. Among authors: krhovska p. Br J Haematol. 2020 May;189(4):e122-e125. doi: 10.1111/bjh.16547. Epub 2020 Mar 4. Br J Haematol. 2020. PMID: 32130732 Free article. No abstract available.
Prospective study of signalling pathways in myeloma bone disease with regard to activity of the disease, extent of skeletal involvement and correlation to bone turnover markers.
Minarik J, Hermanova Z, Petrova P, Hrbek J, Zapletalova J, Krhovska P, Flodr P, Pika T, Bacovsky J, Flodrova P, Herman M, Scudla V. Minarik J, et al. Among authors: krhovska p. Eur J Haematol. 2016 Aug;97(2):201-7. doi: 10.1111/ejh.12708. Epub 2015 Dec 21. Eur J Haematol. 2016. PMID: 26613192
15 results